8-K: Ultragenyx and Mereo BioPharma Announce Positive 14-Month Results for Setrusumab in Osteogenesis Imperfecta

Ultragenyx and Mereo BioPharma reported positive 14-month results from a Phase 2 study showing setrusumab significantly reduced fractures and improved bone mineral density in patients with osteogenesis imperfecta.

Summary

• Ultragenyx Pharmaceutical Inc. and Mereo BioPharma Group plc announced positive 14-month results from the Phase 2 portion of their ongoing Phase 2/3 Orbit study for setrusumab (UX143).
• The study demonstrated a significant reduction in the incidence of fractures in patients with osteogenesis imperfecta (OI) after at least 14 months of follow-up.
• Treatment with setrusumab also resulted in ongoing and meaningful improvements in lumbar spine bone mineral density (BMD) at month 12.
• The median annualized rate of radiologically confirmed fractures was reduced by 67% from 0.72 to 0.00 after a mean treatment duration of 16 months.
• The mean increase in lumbar spine BMD from baseline was 22% at 12 months, improving from 14% at six months.
• The mean baseline lumbar spine BMD Z-score improved from -1.73 to -0.49 at 12 months, a substantial normalization of +1.25.
• These improvements in BMD and Z-scores were consistent across all OI sub-types studied.
• No treatment-related serious adverse events were observed, and reported adverse events were generally consistent with previous studies.

Sentiment

Score: 9

Explanation: The document presents very positive clinical trial results with significant improvements in fracture rates and bone mineral density, indicating a high likelihood of success for the drug. The absence of serious adverse events further boosts the positive sentiment.

Positives

• The study showed a significant 67% reduction in the median annualized fracture rate.
• There was a substantial 22% mean increase in lumbar spine BMD at 12 months.
• The lumbar spine BMD Z-score showed a significant improvement of +1.25 at 12 months.
• The improvements were consistent across all OI sub-types.
• No treatment-related serious adverse events were reported.
• The positive results were sustained over a 14-month period.

Negatives

• The most common adverse events related to the study drug were infusion-related events and headache.
• The study is still ongoing, and further data is needed to confirm long-term efficacy and safety.

Risks

• The clinical development of drugs is inherently uncertain, and regulatory approvals are unpredictable and lengthy.
• There is a risk that results from earlier studies may not be predictive of future study results.
• Adverse side effects could impact the success of the drug.
• The company relies on third-party partners, and the termination of any collaboration agreement could impact the program.
• There is a risk of smaller than anticipated market opportunities for the company's products.
• Manufacturing risks and competition from other therapies could affect the company's success.
• The company's future operating results and financial performance could be affected by various factors.

Future Outlook

The company plans to present more detailed 14-month data at a future scientific meeting. The Phase 3 portion of the Orbit study is ongoing, and the company is also conducting the Phase 3 Cosmic study. The company will continue to develop setrusumab in pediatric and young adult patients with osteogenesis imperfecta.

Management Comments

• The document does not contain direct quotes from management, but it highlights the positive results of the study and the ongoing development of setrusumab.

Industry Context

This announcement is significant for the rare disease space, particularly for osteogenesis imperfecta, where there is a high unmet need for effective treatments. The positive results could position setrusumab as a leading therapy in this area.

Comparison to Industry Standards

• Bisphosphonates are a common treatment for OI, but they have limitations, particularly in long-term efficacy and side effects. Setrusumab's results, showing a significant reduction in fracture rates and improvement in BMD, suggest it could be a more effective treatment option.
• Other companies like Ascendis Pharma are also developing treatments for OI, but the specific results of their trials are not detailed in this document, making a direct comparison difficult.
• The 67% reduction in fracture rate and 22% increase in BMD are substantial improvements compared to typical outcomes with standard care, suggesting a potential new standard of care for OI.

Stakeholder Impact

• Shareholders are likely to react positively to the strong clinical results.
• Patients with osteogenesis imperfecta and their families may have increased hope for a more effective treatment.
• Employees of Ultragenyx and Mereo BioPharma may be motivated by the positive progress of the drug development.
• The positive results could lead to increased interest from potential partners and investors.

Next Steps

• The company will present more detailed 14-month data at a future scientific meeting.
• The Phase 3 portion of the Orbit study is ongoing.
• The Phase 3 Cosmic study is also ongoing.
• All patients in the Phase 3 Orbit study will transition to an extension period and receive open-label setrusumab after the Phase 3 primary analysis is complete.

Key Dates

Keywords

setrusumab, osteogenesis imperfecta, fracture rate, bone mineral density, clinical trial, UX143, Orbit study, Mereo BioPharma, Ultragenyx, BMD